Angiopoietin-2

An angiopoietin that is closely related to ANGIOPOIETIN-1. It binds to the TIE-2 RECEPTOR without receptor stimulation and antagonizes the effect of ANGIOPOIETIN-1. However its antagonistic effect may be limited to cell receptors that occur within the vasculature. Angiopoietin-2 may therefore play a role in down-regulation of BLOOD VESSEL branching and sprouting.

Also Known As:

Networked: 1230 relevant articles (24 outcomes, 153 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	David, Sascha: 21 articles (12/2021 - 01/2008)
2.	Kümpers, Philipp: 20 articles (12/2021 - 01/2008)
3.	Haller, Hermann: 18 articles (12/2021 - 01/2008)
4.	Liles, W Conrad: 15 articles (11/2021 - 02/2011)
5.	Lukasz, Alexander: 14 articles (11/2019 - 01/2008)
6.	Augustin, Hellmut G: 13 articles (01/2022 - 02/2006)
7.	De Palma, Michele: 13 articles (11/2021 - 06/2007)
8.	Parikh, Samir M: 12 articles (01/2022 - 03/2006)
9.	Reiss, Yvonne: 11 articles (12/2021 - 02/2006)
10.	Kielstein, Jan T: 11 articles (07/2015 - 01/2008)

Related Diseases

1.	Neoplasms (Cancer) 11/01/2023 - "Studies have shown that increased angiopoietin-2 (Ang-2) expression relative to Ang-1 expression in tumors is associated with a poor prognosis.The" 01/01/2021 - "Multiregimen survival studies and correlative patient data identified primary tumor-derived Angiopoietin-2 (Ang2) as a potent therapeutic target to restrict lymphogenous tumor cell dissemination. " 08/01/2015 - "Angiopoietin-2 (Ang-2) blocking agents are currently undergoing clinical trials for use in cancer treatment. " 01/01/2015 - "Angiogenesis plays a decisive role in the growth and spread of cancer and angiopoietin-2 (Ang2) is in the spotlight of studies for its unique role in modulating angiogenesis. " 05/01/2006 - "In this study, we analyzed tumor growth, vascularization, and angiopoietin-2 (Ang2) expression during the development of U-87 MG xenografts. "
2.	Inflammation (Inflammations) 04/01/2021 - "The objective of the study was to investigate whether angiopoietin-2 levels are associated with inflammation and CC resistance in PCOS. " 10/22/2021 - "During inflammation, the Tie2 antagonist angiopoietin-2 (Angpt-2) is released from endothelial cells and inhibits Tie2, promoting a prothrombotic phenotypic shift. " 09/01/2021 - "Serum angiopoietin-2 is elevated in patients compared with normal subjects and is correlated with the presence of oral lesions and disease severity, that reflects its role in angiogenesis and inflammation, and angiopoietin-2 serum level could be a potential marker for monitoring the oral lichen to identify possible malignant transformation." 05/17/2021 - "During inflammation, the Tie2 antagonist angiopoietin-2 (Angpt-2) is released from activated endothelial cells and inhibits Tie2, promoting a prothrombotic phenotypic shift. " 01/01/2021 - "Among the MCS cohort, angiopoietin-2 was particularly elevated in patients with systemic congestion and inflammation and was associated with higher incidence of GIB."
3.	Fibrosis (Cirrhosis) 10/01/2022 - "Targeting angiopoietin-2 as a novel treatment option for kidney fibrosis." 06/01/2014 - "This study identifies angiopoietin-2 as a link between kidney fibrosis and arterial stiffness. " 10/01/2022 - "Thus, we defined the detrimental impact of increased angiopoietin-2 on kidney survival of patients with CKD which appears highlighted by angiopoietin-2 induced endothelial CCL2-activated macrophage infiltration and endothelial cell apoptosis in their kidneys undergoing fibrosis." 07/01/2020 - "Of all the angiogenic factors, the gene expression of VEGF and angiopoietin 2 (Ang2) was significantly different between patients with NASH in the early and late fibrosis groups (P < 0.05 for both). " 01/01/2019 - "Considering the prominence of vascular destabilization in decompensated cirrhosis, we evaluated Angiopoietin-2 to predict clinical outcomes. "
4.	Macular Edema 01/01/2021 - "These combinations may help in the early stages of DR. CD5-2, and angiopoietin-2 inhibitors is the third combination and this combination may help to manage diabetic macular edema. " 01/01/2019 - "Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial." 01/01/2012 - "It is possible that the novel selective inhibitors of the inflammatory cascade (like angiopoietin-2, TNFα, and chemokines) may be useful therapeutic agents in the treatment of diabetic macular edema (DME), either alone or in combination with the anti-VEGF drugs." 01/01/2023 - "Clinical trials demonstrated that co-targeting angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF-A) with faricimab controls anatomic outcomes and maintains vision improvements, with strong durability, through 2 years in patients with neovascular age-related macular degeneration and diabetic macular edema. " 09/01/2023 - "Dual inhibition of angiopoietin-2 and VEGF-A with faricimab (Vabysmo) offers excellent visual acuity gains with strong durability in patients with diabetic macular edema (ME) and neovascular age-related macular degeneration. "
5.	Kidney Neoplasms (Kidney Cancer) 01/01/2017 - "Correction: Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers." 12/01/2016 - "Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers."

Related Drugs and Biologics

1.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
2.	Angiopoietin-1
3.	Biomarkers (Surrogate Marker)
4.	faricimab
5.	Transforming Growth Factors (Transforming Growth Factor)
6.	Antibodies
7.	Ranibizumab (Lucentis)
8.	Simvastatin (Zocor)
9.	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
10.	Hydrogen Sulfide (Sulfide, Hydrogen)

Related Therapies and Procedures

1.	Therapeutics
2.	Conservative Treatment
3.	Immunotherapy
4.	Limb Salvage
5.	Bioreactors (Bioreactor)